drugset / Trial / NCT00378235
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
Phase 1/2
Withdrawn
INSYS Therapeutics Inc
Pediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cintredekin besudotox | Protein / enzyme biologic | — | Other |